Featuring Melanie Senior, the author of Evaluate’s Orphan Drugs report, Jeremy M. Levin, CEO of Ovid Therapeutics, and Andreas Hadjivasiliou, Managing Analyst at Evaluate, this discussion covered:
- The potential impact of the IRA on rare diseases and orphan drugs
- The size of the orphan drug market and key areas of growth
- Key players in the market
- The state of the orphan drug pipeline
